BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14137402)

  • 21. [DIABETIC RETINOPATHY AND ITS TREATMENT].
    DENEUMANN PS
    Arch Oftalmol B Aires; 1963 Jul; 38():207-18. PubMed ID: 14085250
    [No Abstract]   [Full Text] [Related]  

  • 22. FAILURE OF NON-17-ALKYLATED ANABOLIC STEROIDS TO PRODUCE ABNORMAL LIVER FUNCTION TESTS.
    MARQUARDT GH; LOGAN CE; TOMHAVE WG; DOWBEN RM
    J Clin Endocrinol Metab; 1964 Dec; 24():1334-6. PubMed ID: 14243179
    [No Abstract]   [Full Text] [Related]  

  • 23. [STUDY OF THE MECHANISM OF ACTION OF ANDROGENS ON ERYTHROPOIESIS].
    NAETS JP; WITTEK M
    C R Hebd Seances Acad Sci; 1964 Nov; 259():3371-4. PubMed ID: 14253249
    [No Abstract]   [Full Text] [Related]  

  • 24. [STUDIES ON DIABETES IN OLD AGE].
    MOHNIKE G; JUTZI E
    Z Gesamte Inn Med; 1963 Oct; 18():884-9. PubMed ID: 14093634
    [No Abstract]   [Full Text] [Related]  

  • 25. [MALNUTRITION IN THE AGED].
    LOEPER J; LOEPER MJ; FORESTIER M
    Prog Med (Paris); 1964 Oct; 92():643-6. PubMed ID: 14227681
    [No Abstract]   [Full Text] [Related]  

  • 26. [Some aspects of pathogenetic therapy of diabetic angiopathies].
    Efimov AS; Skrobonskaia NA; Karabun PM; Danilova AI; Zubkova ST; Naumenko VG; Mankovskiĭ BN; Melńik IM; Malik A; Tkachuk IuV
    Klin Med (Mosk); 1994; 72(1):20-3. PubMed ID: 8196316
    [No Abstract]   [Full Text] [Related]  

  • 27. [URINARY ACID MUCOPOLYSACCHARIDE (AMP) CHANGES IN COMPLICATED DIABETES].
    MINCU I; MIHALACHE N
    Med Interna (Bucur); 1964 Jul; 16():803-10. PubMed ID: 14182761
    [No Abstract]   [Full Text] [Related]  

  • 28. [RESEARCH ON FATIGUE PREVENTION. (ACTION OF 4-HYDROXY-19-NORTESTOSTERONE-17-CYCLOPENTYLPROPIONATE)].
    MAGLIO A; POTENZA P; FRANCESCONI A
    Ann Med Nav (Roma); 1963; 68():797-802. PubMed ID: 14089321
    [No Abstract]   [Full Text] [Related]  

  • 29. [BACTERICIDAL POWER OF THE BLOOD IN PATIENTS CONVALESCING FROM TYPHOID FEVER SUBJECTED TO ANTITYPHOID VACCINATION AND TREATED WITH 4-HYDROXY-19-NORTESTOSTERONE-17-CYCLOPENTYLPROPIONATE].
    LOSCHIAVO F
    G Mal Infett Parassit; 1965 Feb; 17():59-62. PubMed ID: 14327118
    [No Abstract]   [Full Text] [Related]  

  • 30. [COMPLEMENT ACTIVITY IN ATHLETES SUBJECTED TO ANTITETANUS VACCINATION AND TREATED WITH 4-HYDROXY-19-NORTESTOSTERONE-17-CYCLOPENTYLPROPIONATE. II].
    LOSCHIAVO F; GALLO D; BUCCHIARONE A
    Med Sport (Roma); 1965 May; 83():332-6. PubMed ID: 14344534
    [No Abstract]   [Full Text] [Related]  

  • 31. [COMPLEMENT ACTIVITY IN PATIENTS CONVALESCING FROM TYPHOID FEVER SUBJECTED TO ANTITYPHOID VACCINATION AND TREATED WITH 4-HYDROXY-19-NORTESTOSTERONE-17-CYCLOPENTYL-PROPIONATE].
    LOSCHIAVO F
    Riforma Med; 1964 Nov; 78():1253-4. PubMed ID: 14231517
    [No Abstract]   [Full Text] [Related]  

  • 32. Preliminary report of a long acting anabolic agent, nandrolone decanoate.
    CRAIG PE
    Clin Med (Northfield); 1962 May; 69():1154-6. PubMed ID: 13881968
    [No Abstract]   [Full Text] [Related]  

  • 33. [GLUTAMIC-OXALACETIC TRANSAMINASE AND GLUTAMIC-PYRUVIC TRANSAMINASE IN ATHLETES SUBJECTED TO ANTITETANUS VACCINATION AND TREATED WITH 4-HYDROXY-19-NORTESTOSTERONE-17-CYCLOPENTYLPROPIONATE. I].
    LOSCHIAVO F; BUCCHIARONE A; GALLO D
    Med Sport (Roma); 1965 May; 83():327-31. PubMed ID: 14344533
    [No Abstract]   [Full Text] [Related]  

  • 34. [PATHOPHYSIOLOGY OF BLOOD PROTEIN DISORDERS AND GENESIS OF PROTEINS IN DIABETIC ANGIOPATHY. 5. THE PLACE OF THE INTERRENAL SYSTEM AND FUNCTION OF ANABOLIC STEROIDS IN THE DIABETIC-ANGIOPATHIC SERUM PROTEIN METABOLISM].
    BAEHNER KJ
    Z Gesamte Inn Med; 1963 Oct; 18():952-6. PubMed ID: 14093648
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of diabetic retinopathy with anabolic steroids.
    HOUTSMULLER AJ; van POPPEL A
    Ophthalmologica; 1963; 145():185-206. PubMed ID: 13955093
    [No Abstract]   [Full Text] [Related]  

  • 36. STUDIES ON THE NITROGEN BALANCE IN THE HUMAN DURING LONG-TERM TREATMENT WITH DIFFERENT ANABOLIC AGENTS UNDER STRICTLY STANDARDIZED CONDITIONS.
    SAARNE A; BJERSTAF L; EKMAN B
    Acta Med Scand; 1965 Feb; 177():199-211. PubMed ID: 14279501
    [No Abstract]   [Full Text] [Related]  

  • 37. EXPERIMENTAL DIABETIC GLOMERULOSCLEROSIS. II. THE DOG.
    BLOODWORTH JM
    Arch Pathol; 1965 Feb; 79():113-25. PubMed ID: 14232927
    [No Abstract]   [Full Text] [Related]  

  • 38. [CURRENT CLINICAL PROBLEMS IN DIABETOLOGY].
    AUBERTIN E
    J Med Bord; 1964 Oct; 141():1481-96. PubMed ID: 14207813
    [No Abstract]   [Full Text] [Related]  

  • 39. [ON TREATMENT OF DYSPROTIDEMIC SYNDROMES IN GERIATRICS].
    NECCHIDELLASILVA A; SEVERGNINI B
    G Gerontol; 1965 Mar; 13():287-93. PubMed ID: 14335875
    [No Abstract]   [Full Text] [Related]  

  • 40. [SERUM MUCOPOLYSACCHARIDES AND THEIR CHANGES IN THE DEGENERATIVE COMPLICATIONS IN DIABETICS. I].
    MINCU I; MIHALACHE N
    Med Interna (Bucur); 1964 Jun; 16():723-8. PubMed ID: 14170455
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.